Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
FibroGen Inc
Nieuws
FibroGen Inc
FGEN
NAS
: FGEN
| ISIN: US31572Q8087
14/11/2024
0,370 USD
(+11,45%)
(+11,45%)
14/11/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
6 augustus 2022 ·
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
· Persbericht
14 mei 2022 ·
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
· Persbericht
20 augustus 2021 ·
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
· Persbericht
25 juni 2021 ·
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
· Persbericht
11 juni 2021 ·
FIBROGEN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN
· Persbericht
7 juni 2021 ·
Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against FibroGen, Inc.
· Persbericht
2 juni 2021 ·
Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
· Persbericht
28 mei 2021 ·
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
· Persbericht
26 mei 2021 ·
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)
· Persbericht
21 mei 2021 ·
DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in FibroGen, Inc. Securities Fraud Class Action Lawsuit
· Persbericht
17 mei 2021 ·
FGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.
· Persbericht
16 mei 2021 ·
FGEN ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Expanded Class Period
· Persbericht
11 mei 2021 ·
HAGENS BERMAN Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel
· Persbericht
10 mei 2021 ·
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for FibroGen, Inc. Investors - Expanded Class Period
· Persbericht
5 mei 2021 ·
FGEN Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for FibroGen, Inc. Investors
· Persbericht
5 mei 2021 ·
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
· Persbericht
1 mei 2021 ·
Pomerantz Law Firm Announces the Filing of a Class Action Against FibroGen, Inc. and Certain Officers - FGEN
· Persbericht
30 april 2021 ·
Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
· Persbericht
24 april 2021 ·
Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)
· Persbericht
19 april 2021 ·
Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action Lawsuit
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe